Background and Aims: Pharmacological treatment and/or maintenance of remission in inflammatory bowel disease [IBD] is currently one of the biggest challenges in the field of gastroenterology. Here we aimed to assess the anti-inflammatory effect and the mechanism of action of sialorphin, the natural blocker of the endogenous opioid peptide-degrading enzymes neprilysin [NEP] and aminopeptidase N [APN], in mouse models of IBD and the changes in the expression of these enzymes in IBD patients. Methods: We used two models of experimental colitis in mice [2,4,6-trinitrobenzene sulphonic acid [TNBS]-and dextran sulphate sodium [DSS]-induced]. Macroscopic score, ulcer score, colonic wall thickness, and myeloperoxidase [MPO] activity were recorded. Additionally, we measured the expression of NEP and APN in the colon of IBD patients and healthy controls. Results: We showed that sialorphin attenuated acute, semichronic, and relapsing TNBS-induced colitis in mice after systemic administration, and its anti-inflammatory action is associated with mu and kappa opioid receptors. Conclusions: We show that indirect stimulation of opioid receptors by the blockade of NEP and APN is a promising pharmacological strategy for the treatment of IBD, and may become of greater importance than the use of classical opioid agonists.
Introduction
Ulcerative colitis [UC] and Crohn's disease [CD] , which belong to the group of inflammatory bowel diseases [IBD] , are chronic, progressive, and relapsing inflammatory disorders that may cause disability over time. 1, 2 The causes of UC and CD have not been revealed so far, but are thought to be a combination of environmental, genetic, and immunological factors. Both disorders are characterised by an excessive activation of common inflammatory pathways, which results in [13] [14] [15] [16] [17] Sialorphin is the peptide synthesised predominantly in the submandibular gland and prostate of adult rats, and is released locally and systemically in response to stress. It displays potent, naloxonesensitive antinociceptive effect in behavioural models of acute pain. 14 Moreover, it has been shown to enhance sexual behavior and erectile function in male rats. 18, 19 Given the multitude of reports demonstrating that activation of opioid receptors in the GI tract by exogenous agonists improves intestinal inflammation, we aimed at testing the hypothesis that the natural encephalinase inhibitor, sialorphin, can alleviate colonic inflammation in the mouse models of colitis through enhancement of the opioid signalling. [20] [21] [22] [23] [24] [25] [26] We selected sialorphin based on the close phylogenetic relation between its source organism [rat] and the model animal used in this study [mouse] . To date the SMR1 protein, which is a precursor of sialorphin in rat, has not been found in the mouse, which suggests that other proteins with sialorphin-like activity may exist in in this organism or that some other mechanisms [e.g. at the level of expression/degradation] regulate the activity of encephalinases in the mouse. Selective opioid receptor antagonists were employed to investigate the mechanism of action of sialorphin. Moreover, we characterised the expression level of APN as well as NEP in the intestinal biopsies and serum obtained from healthy controls and IBD patients.
Materials and Methods

Animals
Experimentally naive male BALB/c mice were obtained from the vivarium at the University of Lodz, Poland. All animals used in the experiments weighed [22] [23] [24] [25] [26] 
Induction of colitis
TNBS model
Colitis was induced by intracolonic [i.c.] instillation of TNBS, as described before. 27 Briefly, mice were weighed and lightly anaesthesised with 1% isoflurane [Baxter Healthcare Corp., IL, USA] and TNBS [in 0.1 ml of 30% ethanol in saline; acute and semichronic models: 5 mg/animal; chronic relapsing model: first dose 150 mg/kg, second dose 75 mg/kg] were injected into the colon through a catheter inserted 3 cm proximally [measuring from the anus]. Mice were then maintained in an inclined position for 5 min and allowed to recover with food and water supplied. Control animals received vehicle alone [30% ethanol in saline], with TNBS replaced with equivolume water. Preliminary experiments demonstrated that the dose of TNBS used in this study resulted in reproducible colonic inflammation manifested by body weight decrease as well as macroscopic damage and biochemical alterations characteristic of the disease.
DSS model
Colitis was induced by the addition of DSS to drinking water starting from Day 0 to Day 5 [4% wt/vol; molecular weight 40 000; MP Biomedicals, Aurora, OH, Lot No. 5237K]. On Days 6 and 7, the animals received water without DSS. Control animals received tap water. Animal body weight as well as general health and disease progression were monitored daily.
Pharmacological treatments
We used three different therapeutic regimens in the TNBS model. In the acute paradigm, the effect of sialorphin was evaluated as follows: colitis was induced on Day 0 and sialorphin was administered twice daily from Day 0 to Day 2 at doses ranging from 0.3 to 10 mg/ kg intraperitoneally [i.p.], with the first treatment 30 min before the induction of colitis. Mesalazine [5-aminoslicylic acid; 5-ASA] was used as a reference drug and was administered orally [p.o.] at the dose of 50 mg/kg once daily, with the first treatment 30 min before the induction of colitis. 28, 29 Animals were sacrificed on Day 3 and the evaluation of colonic damage was performed [ Figure 1A ]. Selective opioid receptor antagonists were administered i.p. 30 min before sialorphin at the following doses: β-funaltrexamine [β-FNA, 1 mg/kg], nor-binaltorphimine [norBNI, 10 mg/kg], naltrindole [NLTR, 10 mg/kg]. Doses were selected based on the preliminary studies and previously published data. [30] [31] [32] [33] None of the antagonists influenced the observed parameters when given alone.
In the semichronic TNBS model, a curative treatment mode was applied. Inflammation was induced on Day 0 and animals received sialorphin [1 mg/kg, i.p., twice daily] between Day s3 and 6 [ Figure 3A ]. On Day 7 mice were sacrificed, and the evaluation of colonic damage was performed.
The anti-inflammatory effect of sialorphin on chronic, relapsing colitis was evaluated in the model described earlier by Martin et al., 34 with minor modifications. Briefly, colitis was induced on Day 0 by i.c. administration of 150 mg/kg of TNBS. From Day 7 to Day 13, mice were injected with sialorphin at the dose of 1 mg/kg twice daily [i.p.]. Colitis was reactivated on Day 11 with the second injection of 75 mg/ kg of TNBS solution. Three days after the aggravation, mice were sacrificed [ Day 14, endpoint] and the evaluation of colonic damage was performed [ Figure 4A ]. Doses of TNBS used in this experiment were selected based on the preliminary experiments involving titration and evaluation of disease parameters as well as mice survival rate. In all experiments, control animals received vehicle [100 µl i. 
Evaluation of colonic damage
TNBS-induced colitis
Animals were sacrificed by cervical dislocation. The colon was rapidly removed, opened longitudinally, rinsed with phosphate buffered saline [PBS] , and immediately examined. Macroscopic colonic damage was assessed by an established semiquantitative scoring system by adding individual scores for ulcer, colonic shortening, wall thickness, and presence of haemorrhage, faecal blood, and diarrhoea, as described before. 27 For scoring ulcers and colonic shortening, the following scale was used: ulcer, 0.5 points for each 0.5 cm; shortening of the colon, 1 point for > 15%, 2 points for > 25% [based on a mean length of the colon in untreated mice of 8.01 ± 0.15 cm; n = 8]. The wall thickness was measured in millimetres, a thickness of n mm corresponding to n scoring points. The presence of haemorrhage, faecal blood, or diarrhoea increased the score by 1 point for each additional feature.
DSS-induced colitis
Mice were sacrificed by cervical dislocation on Day 7 following addition of DSS to the drinking water. The entire colon was rapidly isolated All measurements were performed in triplicate. MPO was expressed in milliunits per gram of wet tissue, 1 unit being the quantity of enzyme able to convert 1 µmol of hydrogen peroxide to water in 1 min at room temperature. Units of MPO activity per 1 min were calculated from a standard curve using purified peroxidase enzyme.
Histology
After the macroscopic scoring, segments of the distal colon were stapled flat, mucosal side up, onto cardboard and fixed in 10% neutralbuffered formalin for 24 h at 4°C. Samples were then dehydrated, embedded in paraffin, sectioned at 5 μm and mounted onto slides. Subsequently sections were stained with haematoxylin and eosin and examined using a Motic AE31 microscope [Ted Pella, Sweden]. Photographs were taken using a digital imaging system consisting of a digital camera [ 
Study population for the evaluation of human NEP and APN levels
To quantify the relative expression of human NEP and APN, forceps biopsy samples and serum were analysed. In total, 35 specimens prepared from human colon biopsies and 56 serum samples were used for the study. The study population comprised 17 . The specimens were frozen shortly after isolation and kept at -80ºC until further analysis. The diagnosis of CD and UC in patients was assessed accordingly to established clinical criteria using endoscopic, radiological, and histopathological criteria. This human part of the study was approved by the Ethics Committee of the Medical University of Lodz. All patients gave written, informed consent before the analysis.
Determination of APN and NEP mRNA levels
The RNA was isolated according to manufacturer's protocol using the PureLink RNA Mini kit [Life Technologies, Carlsbad, CA, USA] as described before. 36 Sialorphin was synthesised by solidphase method using Fmoc chemistry. Particulars concerning the synthesis, purification, and physicochemical characteristics of this peptide are as described previously. 38 All drugs were dissolved in 5% dimethyl sulphoxide [DMSO] in saline, which was used as vehicle. The vehicles in the concentrations used had no effects on the observed parameters. 
Results
Sialorphin exhibits anti-inflammatory effect in TNBS-induced colitis through MOR and KOR
To evaluate the anti-inflammatory activity of sialorphin in the mouse GI tract, we used a well-established mouse model of acute colitis induced by TNBS. The i.c. instillation of TNBS resulted in a reproducible colitis in mice, manifested by increased macroscopic colon damage scores and elevated MPO activity; 5-ASA, which was used as a reference drug, administered orally at the dose of 50 mg/kg [once daily], significantly attenuated colitis as shown by decreased macroscopic and ulcer scores, reduced colonic wall thickness, and MPO activity [ Figure 1B- To further characterise the mechanism of action of sialorphin in the TNBS model, we used selective antagonists of MOR, KOR, and DOR receptors [β-FNA, norBNI, and NLTR, respectively]. As shown in Figure 2B -E, the anti-inflammatory effect of sialorphin was significantly blocked by MOR and KOR antagonists.
Literature data and our previous observations indicate that the severity of clinical symptoms of colitis, such as changes in body weight, reach maximum at Day 3 after TNBS injury. 39, 40 To investigate the effect of sialorphin on established colitis, we administered the compound twice daily from Day 3 following the instillation of TNBS. Treatment with sialorphin resulted in a significant attenuation of colitis as demonstrated by decreased macroscopic score, ulcer score, colonic wall thickness. and MPO activity [ Figure 3B -E].
Subsequently, we evaluated the effect of sialorphin in the chronic, relapsing colitis paradigm that mimics the pattern of symptoms that occur in humans [including the acute phase of colitis and the recovery and relapse periods]. Sialorphin [1 mg/kg, i.p.] administered twice daily from Day 7 to Day 13, significantly alleviated clinical and biochemical parameters of the disease as shown by reduced macroscopic and ulcer scores, colonic wall thickness, and MPO activity [ Figure 4B -E], as well as decreased body weight loss [ Figure 4F ] and expression of pro-inflammatory cytokines, namely TNFα and IL-1β [ Figure 4G , H]. Histological evaluation of the mouse colon specimens supported the macroscopic observations, showing the decrease in pathological changes after treatment with sialorphin [ Figure 5 ]. Analysis of sections of distal colon from untreated animals showed intact epithelium, absence of oedema, and normal muscle architecture [ Figure 5A ]. Severe microscopic damage, characterised by loss of mucosal architecture, thickening of smooth muscle, presence of crypt abscesses, and extensive cellular infiltration was observed in TNBS-treated colon specimens [ Figure 5B ]. The histological damage score was reduced after i.p. sialorphin [1 mg/kg twice daily from Day 7 to Day 13; Figure 5C ].
Sialorphin has no effect on DSS-induced colitis in mice
In order to extend our observations on the anti-inflammatory action of sialorphin, a DSS-induced mouse model of UC was used. Animals treated with 4% DSS in drinking water developed severe colonic injury, which was not reversed by i.p. administration of sialorphin [1 mg/kg, twice daily during 6 days, Figure 6 ]. Treatment with sialorphin did not reduce any of evaluated parameters: macroscopic colon damage score [ Figure 6B ], colon weight [ Figure 6C ], colon length [ Figure 6D ], MPO activity [ Figure 6E ], and body weight loss [ Figure 6F ].
Expression of APN and NEP in the human colon is altered during CD and UC
To translate our observations from animals to human conditions, we examined APN and NEP mRNA and protein expression levels in colon specimens [membrane-anchored form of the enzymes] as well as serum [soluble form of the enzymes] from patients with CD and UC and healthy controls [HC] . We found that the relative expression of APN mRNA in the colonic tissue is increased in patients with CD and UC, although in the case of UC the difference did not reach statistical significance [ Figure 7A ]. On the other hand, the expression of NEP mRNA in the colonic tissue is not altered in CD and tends to decrease [p = 0.09] in UC patients [ Figure 7B ].
Western blot analysis of protein expression in the colon did not show significant changes in the level APN [ Figure 7C ]. In contrast, the expression of NEP protein was elevated in CD patients, although the difference did not reach statistical significance [p = 0.09; Figure 7D ].
Determination of APN and NEP levels in the serum did not show any differences between HC and CD/UC [ Figure 7F , G]. 
Discussion
Evaluating novel options for the treatment of IBD, we characterised the anti-inflammatory action of the natural APN and NEP inhibitor sialorphin in the mouse models of intestinal inflammation. We showed that sialorphin displays anti-inflammatory activity in the TNBS-induced mouse model of experimental colitis, and this effect was mediated by MOR and KOR receptors. We also showed that sialorphin is effective in the model of chronic, relapsing colitis that recapitulates the course of IBD in humans, a finding of high clinical relevance. Finally, we quantified the expression of APN and NEP in human colonic specimens, to evaluate the potential involvement of these enzymes in the pathophysiology of IBD. For many years, opiates have been known to affect a number of processes related to the central and peripheral nervous systems, such as analgesia, locomotor activity, mood-related behaviour, GI motility, and immune response. Various structural and functional components that express opioid receptors are responsible for the proper function of the GI tract, including the ENS, GI smooth muscle cells, and the intestinal mucosa and immune cells. Opioid receptors play a major role in the regulation of the GI transit, mucosal transport of fluids, and maintaining GI homeostasis. Furthermore, opioid ligands have been shown to modulate immune cell function as well as activation status. 9 However, despite the efforts that have been put into the development of novel anti-inflammatory opioid drugs, none of these have reached clinical trials in IBD, which is most likely due to the vast spectrum of adverse effects caused by these compounds, encompassing sleep disorders, seizures, hallucinogenic effects, and dependence. 41 Relatively recent elucidation of the role of endogenous opioid peptide-inactivating metalloectopeptidases in many pathophysiological conditions made them an attractive pharmacological target that can be used to enhance opioid signalling, bypassing adverse side effects. Metalloectopeptidase inhibitors, in contrast to classical receptor ligands, modulate only existing molecular signalling; thus it is very unlikely for the signalling pathways to become permanently switched on/off. Such a strategy lowers the likelihood of losing the control over signal transduction on the cellular level. Furthermore, the action of protease inhibitors may be limited in time and space, which ensures accurate pharmacological control over their effects with concomitant potent anti-inflammatory effect. The significant anti-inflammatory action of sialorphin demonstrated in this study suggests a possible therapeutic use of APN/NEP inhibitors in the treatment of IBD, additionally supported by the fact that therapeutic effect of sialorphin is reversed by selective blockers of MOR and KOR receptors. Previous studies showed that the expression of both receptors is up-regulated in the TNBS-treated animals and demonstrated beneficial, anti-inflammatory effects of dual MOR-KOR activation in the GI tract. 25, 31 However, the present study shows for the first time that this can be achieved also indirectly, by blockade of the endogenous opioid peptide-degrading enzymes. The involvement of KOR in the anti-inflammatory action of sialorphin suggests that this compound may also act as an inhibitor of local degradation of dynorphin [the main endogenous KOR activator]. Indeed, very recently it has been shown that opiorphin, which is a functional analogue of sialorphin, blocks the local bioconversion of dynorphin in the rat brain. 42 Several lines of evidence show that the stimulation of opioid receptors can help prevent overt pathological changes in the course of intestinal inflammation. It has been shown that MOR agonists DALDA and DAMGO improve colitis in mice. 20 Moreover, MOR knockout animals are more sensitive to inflammation than the wild type. 20 Stimulation of MOR protects against bowel injury through regulation of T cell proliferation, cytokine production, increased expression of cytoprotective genes [Ccnd1, Cox2, myc], and improved wound healing. 20, 26 The anti-inflammatory properties of KOR stimulation have also been reported. Aviello et al. showed that the natural KOR agonist, salvinorin A [SA], reduces LPS-stimulated secretion of TNFα, IL-10, and iNOS in macrophages. 43 In vivo SA protects against LPS-and carrageenaninduced oedema as well as TNBS-and DSS-colitis. 35, 43 Of note, it has been observed that the effects of SA in the GI tract were more potent in the pathophysiological conditions, suggesting that KORs represent a potential target for the treatment of intestinal disorders. 44 In parallel, Philippe et al. reported that the expression of MOR in both small and large intestine is significantly elevated in IBD vs healthy subjects. 21 The cellular source of MOR in the GI tract of IBD patients includes CD4 + and CD8 + T cells and neuronal cell bodies of submucosal and myenteric plexuses. Moreover, human biopsies treated ex vivo with opioid agonist DALDA express less TNFα than untreated controls. 21 Our results show that the expression of membrane APN and NEP seems to be altered in IBD patients, suggesting that these enzymes also contribute to the pathophysiology of intestinal inflammation. Increased expression of the endogenous opioid-degrading enzymes is very likely to inhibit basal opioid signalling in the gut, which may be a cause of impaired intestinal motility, permeability, and pain signalling as observed in IBD patients. Hence, to combat these changes, we propose treatment with natural, dual APN-NEP inhibitor, which indeed alleviated colitis in mice in the models mimicking the symptoms and the course of CD in humans.
In addition, the anti-inflammatory action of sialorphin was assessed in the DSS model of colitis in which, in contrast to the TNBS-induced model, it did not exhibit therapeutic effect. The lack of beneficial effect may be caused by the percentage of DSS used to induce inflammation and/or by the dose of sialorphin used for the treatment. Indeed, severe damage caused by DSS can mask the potential effect of the test compound. Furthermore, we may postulate that this observation arises from the difference between the mechanisms underlying the pathogenesis of DSS-and TNBS-induced colitis at the molecular and cellular levels. The inflammatory pathways activated in DSS and TNBS mouse models of colitis are related, but not identical. 44 They share the common pathway of inflammation, mediated by an excessive Th1 or Th2 response; however, several significant, model-based differences can be indicated. First of all, these two models are characterised by different profile of pro-inflammatory cytokines secreted by immune cells. DSS up-regulates the secretion of TNFα and IL-4 -5 -6 -17 and keratinocyte-derived chemokines, which are mainly responsible for the tissue damage. In the TNBS model, the main role of TNFα is to stimulate the secretion of IL-2 -12 and IL-18 by T cells. 45, 46 In the TNBS model, the immunological response [similar to delayed-time hypersensitivity reaction] is elicited by reaction to a specific antigen [a hapten], which interacts with amino groups of colonic and potentially also bacterial proteins, and it is mainly mediated by Th1 cells. DSS leads to the activation of lymphocytes and M1 type of macrophages that inhibit cell proliferation and cause tissue erosion and ulceration, as well as the induction of Th1 and/or Th2 responses. An imbalance in epithelial proliferation and apoptosis has also been implicated in the mechanism of DSS action. We therefore postulate that these differences in the pathomechanisms underlying colitis underpin the lack of anti-inflammatory action of sialorphin in the DSS-induced model of colitis. Moreover, since TNBS-induced colitis is widely regarded as a model of CD and DSS-induced colitis as a model of UC, it may be suggested that the inhibition of APN and/or NEP would be more effective in the former.
4.1.Conclusions
In conclusion, in the present study we showed that sialorphin exerts potent anti-inflammatory effect in the mouse model of TNBSinduced colitis, which is principally mediated by the MOR and KOR receptors. Since the blockade of APN and/or NEP produces effects similar to those that can be achieved by the opioid receptor agonists, it has been suggested to be an attractive solution for the treatment of IBD in humans, possibly without the side effects typical for opioids. Our observations promote a novel strategy in IBD treatment, based on the regulation of opioid signalling through inhibition of encephalinases. Design and synthesis of novel encephalinase inhibitors is thus a promising direction in the search for novel anti-IBD drugs. The novel therapy may be particularly appealing for the group of patients for whom other therapies do not provide sufficient relief. 
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